Korea United Pharm
KOREA UNITED PHARM is a leading pharmaceutical company specializing in the development of improved new drugs, with a strong global network and advanced R&D capabilities. The company has established a smart factory certified for high-quality pharmaceutical manufacturing and exports to over 40 countries. Committed to social responsibility, it actively engages in social contribution activities and fosters young talent for the global pharmaceutical industry.
Industries
Nr. of Employees
large (251-1000)
Korea United Pharm
Patents
Pharmaceutical composition comprising THA as active ingredient for treating breast cancer
US-11793772-B2
View DetailsPharmaceutical composition comprising THA as effective ingredient for treatment of prostate cancer
US-11484511-B2
View DetailsOral complex preparation comprising fat-soluble drug and solid preparation coated with oil-proof material
US-11033505-B2
View Details
Pharmaceutical composition comprising THA as active ingredient for treating breast cancer
US-11793772-B2
View DetailsPharmaceutical composition comprising THA as effective ingredient for treatment of prostate cancer
US-11484511-B2
View DetailsOral complex preparation comprising fat-soluble drug and solid preparation coated with oil-proof material
US-11033505-B2
View DetailsProducts
Combination lipid-lowering capsule (pitavastatin + fenofibric acid)
Fixed-dose combination oral capsule of pitavastatin and fenofibric acid formulated with bioavailability enhancement technology and enteric coating to enable dose efficiency, improved solubility and reduced GI adverse effects; reported in-house synthesis of both active ingredients.
Finished product portfolio (general statement)
A diversified portfolio of finished pharmaceutical products, reported as over 200 product SKUs including approximately 30 anticancer agents, antibiotics, vitamins and other specialty and general medicines distributed domestically and exported internationally.
Combination lipid-lowering capsule (pitavastatin + fenofibric acid)
Fixed-dose combination oral capsule of pitavastatin and fenofibric acid formulated with bioavailability enhancement technology and enteric coating to enable dose efficiency, improved solubility and reduced GI adverse effects; reported in-house synthesis of both active ingredients.
Finished product portfolio (general statement)
A diversified portfolio of finished pharmaceutical products, reported as over 200 product SKUs including approximately 30 anticancer agents, antibiotics, vitamins and other specialty and general medicines distributed domestically and exported internationally.
Services
Structured programs to solicit collaboration proposals and technology partnerships for mutual development.
Export and international distribution of finished pharmaceutical products through overseas offices and local production sites.
Integrated in-house capability to synthesize active ingredients and produce finished dosage forms; may support external manufacturing partnerships.
Structured programs to solicit collaboration proposals and technology partnerships for mutual development.
Export and international distribution of finished pharmaceutical products through overseas offices and local production sites.
Integrated in-house capability to synthesize active ingredients and produce finished dosage forms; may support external manufacturing partnerships.
Expertise Areas
- Modified-release and reformulation development
- Formulation development and bioavailability enhancement
- Drug delivery systems and device-associated formulations
- Pharmaceutical manufacturing and scale-up
Key Technologies
- Smart factory automation
- Quality by Design (QbD)
- Bioavailability enhancement techniques (solubilization, alkalization)
- Enteric coating technology
News & Updates
Korea United Pharm. has received approval for its new combination drug 'Pitaric Capsule' containing active phenobric acid, which can be taken regardless of meals, using its proprietary EH technology to improve bioavailability.
Korea United Pharm. collaborated with Ajou University to provide pharmacy students with a manufacturing site tour to understand the pharmaceutical industry and explore career opportunities.
The company operates in 48 countries, with certified facilities and awards recognizing its innovation and export achievements.
Korea United Pharm. received the Korea New Drug Development Technology Award
Recognized for its innovative drug development technology.
Korea United Pharm. awarded the Korea Excellent Patent Award
Honored for its patent achievements in the pharmaceutical industry.
Over $20 million in exports, awarded the Top Exporter Trophy
Achieved significant export milestones in the pharmaceutical sector.
Korea United Pharm. has received approval for its new combination drug 'Pitaric Capsule' containing active phenobric acid, which can be taken regardless of meals, using its proprietary EH technology to improve bioavailability.
Korea United Pharm. collaborated with Ajou University to provide pharmacy students with a manufacturing site tour to understand the pharmaceutical industry and explore career opportunities.
The company operates in 48 countries, with certified facilities and awards recognizing its innovation and export achievements.
Korea United Pharm. received the Korea New Drug Development Technology Award
Recognized for its innovative drug development technology.
Korea United Pharm. awarded the Korea Excellent Patent Award
Honored for its patent achievements in the pharmaceutical industry.
Over $20 million in exports, awarded the Top Exporter Trophy
Achieved significant export milestones in the pharmaceutical sector.